Skip to main content

Advertisement

SpringerLink
Log in

Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph+CD34+CD38neg) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319–325.

    Article  CAS  Google Scholar 

  2. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532–4539.

    Article  CAS  Google Scholar 

  3. Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926–935.

    Article  CAS  Google Scholar 

  4. Bocchia M, Ippoliti M, Gozzetti A, Abruzzese E, Calabrese S, Amabile M et al. CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. Leukemia 2008; 22: 426–428.

    Article  CAS  Google Scholar 

  5. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701–4707.

    CAS  Google Scholar 

  6. Mahon FX, Huguet F, Guilhot F, Legros L, Nicolini FE, Charbonnier A et al. Is it possible to stop imatinib in patients with chronic myeloid leukemia? An update from a French Pilot Study and first results from the multicentre « Stop Imatinib » (STIM) Study. Blood 2008; 112, Abstract 187.

  7. Takahashi N, Miura I, Saitoh K, Miura AB . Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood 1998; 92: 4758–4763.

    CAS  PubMed  Google Scholar 

  8. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25: 1315–1321.

    Article  CAS  Google Scholar 

  9. Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008; 111: 2843–2853.

    Article  CAS  Google Scholar 

  10. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007; 110: 4427–4435.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Finnish special governmental subsidy for health sciences, research, and training, by the Finnish Cancer Societies, Emil Aaltonen Foundation, Academy of Finland, Finnish Medical Foundation, Blood Disease Foundation, Biomedicum Helsinki Foundation, Gyllenberg Foundation, IGA NS 9949-3 and KA Johansson foundation. The authors would like to thank the personnel at the Hematology Research Unit at Helsinki and flow cytometry laboratory, HUSLAB for their expert technical assistance.

Author information

Authors and Affiliations

  1. Hematology Research Unit, Biomedicum Helsinki, Helsinki University Central Hospital, Helsinki, Finland

    S Mustjoki, P Rohon, S Jalkanen, P Koskenvesa, T Lundán & K Porkka

  2. Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland

    S Mustjoki

  3. Department of Medicine, Division of Hematology, Helsinki University Central Hospital, Helsinki, Finland

    S Mustjoki, P Koskenvesa & K Porkka

  4. Department of Hemato-oncology, University Hospital Olomouc, Olomouc, Czech Republic

    P Rohon

  5. Department of Clinical Chemistry, Institute of Diagnostics, Oulu University Hospital, Oulu, Finland

    K Rapakko

  6. Laboratory of Molecular Pathology, HUSLAB, Helsinki University Central Hospital, Helsinki, Finland E-mail: kimmo.porkka@helsinki.fi,

    T Lundán

Authors
  1. S Mustjoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Rohon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Rapakko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Jalkanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Koskenvesa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Lundán
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Porkka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Porkka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mustjoki, S., Rohon, P., Rapakko, K. et al. Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph+CD34+CD38neg) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy. Leukemia 24, 219–222 (2010). https://doi.org/10.1038/leu.2009.190

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.190

  • Springer Nature Limited

This article is cited by

Search

Navigation